NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

Opinion|Videos|August 8, 2024

Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Luspatercept

Author(s)Mikkael Sekeres, MD

Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.

Episodes in this series

1 KOL is featured in this program

EP. 1 Anemia in Lower-Risk MDS: Introduction and Case Presentation

1 KOL is featured in this program

EP. 2 Lower-Risk MDS: Frontline Therapy Initiation and Determination of Treatment Failure

1 KOL is featured in this program

EP. 3 Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Imetelstat

1 KOL is featured in this program

EP. 4 Patient Treatment Goals for Lower-Risk MDS

1 KOL is featured in this program

EP. 5 Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Luspatercept

1 KOL is featured in this program

EP. 6 Optimizing Anemia Management in Lower-Risk MDS: Key Takeaways

1 KOL is featured in this program

EP. 7 Second-Line Therapy for ESA-Refractory, Transfusion Dependent Lower-Risk MDS: Lenalidomide

1 KOL is featured in this program

EP. 8 Second-line Treatment for RS-negative Lower-Risk MDS: Choosing Between EMA and Telomerase Inhibitor Options

1 KOL is featured in this program

EP. 9 Adverse Event Profile and Management of Imetelstat

Please discuss how you approach second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients.

(LUSPATERCEPT)

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

1 expert is featured in this series.

Clinical Framing and Prognostic Assessment in Progressive Small Bowel Neuroendocrine Tumors

ByChristopher Lieu, MD, FASCO

February 1st 2026

Experts featured in this series.

Future Directions in cGVHD Treatment

ByLeyla O. Shune, MD

January 26th 2026

Later-Line and Combination Therapies in cGVHD and Future Directions

ByZachariah DeFilipp, MD

January 23rd 2026

Experts featured in this series.

Sequencing in the cGVHD Treatment Paradigm

ByLeyla O. Shune, MD

January 19th 2026

Second-Line Therapy and Ruxolitinib for cGVHD

ByZachariah DeFilipp, MD

January 16th 2026

Latest CME

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

43rd Annual Miami Breast Cancer Conference®

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The Targeted Pulse: New Standards in Myeloma, Melanoma, and More

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC

NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC

Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers